Association between polypharmacy and health-related quality of life among cancer survivors in the United States.

摘要: Polypharmacy (PP) is present in many cancer survivors and may lead to lower health-related quality of life (HRQoL). The study’s objective was evaluate the association between PP HRQoL among US. A cross-sectional analysis Medical Expenditure Panel Survey (MEPS) conducted. Our analytic sample included all adult patients with cancer, during even years 2008–2014. defined as reported use five or more unique therapeutic classes prescription medications. MEPS measured using Short Form 12-Item Health Version 2 (SF-12v2) physical component summary (PCS) mental (MCS) scores. Ordinary least squares regressions were used assess associations controlling for demographic, socioeconomic, clinical factors. prevalent 44.4% 10.1 million per calendar year (on average) 2008, 2010, 2012, 2014. mean adjusted PCS score 35.8 points, which significantly compared without (39.5) by 3.7 points (p value < .0001). Conversely, MCS scores not (44.9 versus 45.4, p value = 0.3145). associated poorer than their counterparts PP. should be examined closely because increased HRQoL.